Lin and co-workers found that T3/TR treatment reduced TUG1 expression in vitro, resulting in the downregulation of alfa fetoprotein (AFP) mRNA in patients with non-hepatitis B/non-hepatitis C HCC (NBNC-HCC) (Lin et al., 2020). The gene discussed is TUG1; the disease is hepatitis C virus infection.